Sponsor Deadline
Posted: 4/30/2024

Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01, R03, R21)

This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.

Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

This FOA will utilize the R01 funding mechanism and runs in parallel with two FOAs of identical scientific scope, PAR-21-354  and PAR-21-355, that encourage applications under the R03 and R21 grant mechanisms.


  • R01 Deadlines: Feb. 5, Jun. 5, Oct. 5.
  • R03 and R21 Deadlines: Feb. 16, Jun. 16, Oct. 16

PAR-21-353 Expiration Date: November 06, 2024